Amneal Pharmaceuticals announced on Monday, October 27, 2025, the U.S. commercial launch of Brekiya® (dihydroergotamine mesylate) injection, the first and only ready‑to‑use dihydroergotamine (DHE) autoinjector approved for the acute treatment of migraine with or without aura and cluster headaches in adults. The product is now available by prescription exclusively through Walgreens Specialty Pharmacy and Sterling Specialty Pharmacy.
Brekiya® offers patients a convenient, self‑administered option that eliminates the need for emergency‑room visits during severe headache attacks. The launch expands Amneal’s specialty portfolio into a high‑growth therapeutic area, addressing a market where only a few treatment options exist for cluster headache and where migraine remains the fourth most common reason for U.S. emergency department visits.
The commercial availability of Brekiya® represents a significant revenue opportunity for Amneal, positioning the company to capture a share of the U.S. migraine and cluster headache market and reinforcing its strategy to diversify beyond traditional generics into specialty and complex injectable products.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.